Watson Pharmaceuticals, Inc. announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Nabumetone tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly.

Nabumetone had total US sales of $58 million for the twelve months ending April 30, 2011, according to IMS Health. Nabumetone is indicated for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health.